NCT00581425已完成4 期
Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp
The University of Texas Health Science Center, Houston2 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2007年12月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 49
- 试验地点
- 2
- 主要终点
- resolution of basal cell carcinoma
研究概览
简要总结
A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Nodular or superficial basal cell carcinoma on the skin excluding scalp or face
排除标准
- •Pregnancy
结局指标
主要结局
resolution of basal cell carcinoma
时间窗: 2 years
次要结局
- resolution of basal cell carcinoma at a lower cost and less inflammation.(2 years)
研究者
Stephen Tucker
Visiting Professor - Dermatology
The University of Texas Health Science Center, Houston
研究点 (2)
Loading locations...
相似试验
Unknown
3 期
Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell CarcinomaNodular Basal Cell CarcinomaNCT02242929Maastricht University Medical Center145
暂停
不适用
Curettage Versus Excision in Nodular and Superficial Basal Cell CarcinomasCarcinoma, Basal CellNCT00515970University Hospital Tuebingen400
已完成
2 期
Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck ReconstructionWound HealingSurgical WoundGraft FailureNCT06634030Vanderbilt University Medical Center36
已完成
3 期
Aldara for the Treatment of Large and/or Multiple sBCCCarcinoma, Basal CellNCT00189280MEDA Pharma GmbH & Co. KG111
已完成
2 期
Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell CarcinomaCarcinomaNCT03546166Centre Hospitalier Universitaire de Nice24